Production (Stage)
Addex Therapeutics Ltd
ADXN
$8.40
$0.192.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -97.27% | -51.22% | |||
| Total Other Revenue | -100.00% | -- | |||
| Total Revenue | -97.48% | -47.06% | |||
| Cost of Revenue | -68.53% | -36.81% | |||
| Gross Profit | 56.98% | 31.47% | |||
| SG&A Expenses | -21.02% | -26.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -35.28% | -29.88% | |||
| Operating Income | 29.47% | 27.66% | |||
| Income Before Tax | 23.28% | -9.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.28% | -9.63% | |||
| Earnings from Discontinued Operations | -546.43% | -100.02% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.38% | -112.42% | |||
| EBIT | 29.47% | 27.66% | |||
| EBITDA | 26.94% | 24.45% | |||
| EPS Basic | 22.22% | -112.42% | |||
| Normalized Basic EPS | 23.21% | -9.80% | |||
| EPS Diluted | 39.66% | -116.01% | |||
| Normalized Diluted EPS | 23.21% | -86.67% | |||
| Average Basic Shares Outstanding | 0.03% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.03% | -41.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||